PUBMED is run by the NIH in the US, and has over 1 million studies and abstracts that you can search through. If the whole study is not on the PUBMED site itself, there is often a link to the whole study on another site. The studies are for and against using hydroxychloroquine, commonly abbreviated “HCQ”. This can be a great starting point to find research on both sides of the issue.
https://pubmed.ncbi.nlm.nih.gov/?term=hydroxychloroquine+coronavirus
You can even save the results of the search to a text file in various formats. The “Summary (text)” format is a bibliography with no abstract. One “Summary (Text)” entry looks like this:
5: Zaidel EJ, Wyss Quintana FS, Sosa Liprandi Á, Mendoza I, Márquez MF, Nuñez E,
Barbosa M, Baranchuk A. Hidroxicloroquina. Mensajes desde la cardiología en
tiempos de pandemia por coronavirus [Hydroxychloroquine. Cardiology’s viewpoint
in times of coronavirus pandemic]. Medicina (B Aires). 2020;80(3):271-274.
Spanish. PMID: 32442941.
The “Abstract (text)” format is plain text and has more information for each search result, and looks like this:
5\. Medicina (B Aires). 2020;80(3):271-274.
[Hydroxychloroquine. Cardiology’s viewpoint in times of coronavirus pandemic].
[Article in Spanish; Abstract available in Spanish from the publisher]
Zaidel EJ(1), Wyss Quintana FS(2), Sosa Liprandi Á(2), Mendoza I(2), Márquez
MF(2), Nuñez E(2), Barbosa M(2), Baranchuk A(2).
Author information:
(1)Grupo de Trabajo COVID-19 de la Sociedad Interamericana de Cardiología.
E-mail: ezezaidel@gmail.com.
(2)Grupo de Trabajo COVID-19 de la Sociedad Interamericana de Cardiología.
Comment in Medicina (B Aires). 2020;80 Suppl 3:89-90.
Due to the coronavirus disease 2019 (COVID-19) pandemic, a wide number of
compounds are under scrutiny regarding their antiviral activity, one of them
being hydroxychloroquine. Cardiac aspects of the use of chloroquine and
hydroxychloroquine are reviewed in this manuscript. A non-systematic review of
the medical literature was performed. Information about their safety and
efficacy as antimalarials, antivirals, as well as in the long-term treatment of
rheumatic diseases was collected. We found an anti-inflammatory effect with
reduction of longterm cardiovascular events, a very infrequent heart disease due
to a lysosomal effect of the drug, and at the hemodynamic level hypotension,
tachycardia, and QT interval prolongation, exacerbated when combined with
azithromycin. However, the rate of adverse cardiac events of hydroxychloroquine
(and chloroquine) was low.
Publisher: Ante la pandemia de COVID-19 (del inglés coronavirus disease 2019),
uno de los fármacos propuesto para su tratamiento es la hidroxicloroquina. Se
revisan aquí aspectos cardiológicos del uso de cloroquina e hidroxicloroquina.
Se realizó una revisión no sistemática en la literatura médica orientada a la
búsqueda de información acerca de su seguridad y eficacia como antimaláricos y
antivirales, así como en el tratamiento prolongado de enfermedades
reumatológicas. Se halló un efecto antiinflamatorio con reducción de eventos
cardiovasculares a largo plazo, una cardiopatía muy infrecuente por un efecto
lisosomal del fármaco, y a nivel hemodinámico hipotensión, taquicardia, y
prolongación del intervalo QT, exacerbado si se combina con azitromicina. Sin
embargo, la tasa de eventos adversos cardíacos de la hidroxicloroquina y la
cloroquina fue baja.
PMID: 32442941 [Indexed for MEDLINE]
